Sutro Biopharma, Inc. (STRO)
| Market Cap | 1.18B |
| Revenue (ttm) | 45.75M |
| Net Income (ttm) | 12.63M |
| Shares Out | 35.88M |
| EPS (ttm) | 0.44 |
| PE Ratio | 60.41 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $26.64 |
| Previous Close | $25.93 |
| Change ($) | 0.71 |
| Change (%) | 2.74% |
| Day's Open | 25.75 |
| Day's Range | 25.73 - 27.82 |
| Day's Volume | 688,022 |
| 52-Week Range | 6.19 - 27.82 |
Sutro is a leader in CFPS and has major collaborations to prove it. Its early data is a lethal late line cancer is very promising.
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicatio...
SOUTH SAN FRANCISCO, Calif., Dec. 8, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicatio...
iBio (NYSE: IBIO) shares are trading lower on Tuesday after the company announced a common stock offering. iBio's main area of business is plant-based protein expression technologies for vacci...
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicatio...
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicatio...
One of the company's pipeline treatments shows encouraging results in ovarian cancer patients.
Sutro Biopharma (NASDAQ: STRO) shares are trading higher on Friday after the company announced interim data on its STRO-002 Phase 1 dose-escalation study for patients with ovarian cancer. Sutr...
Sutro Biopharma (STRO) is on the rise Friday with heavy trading of STRO stock despite the company not announcing anything new today. The post Sutro Biopharma: 7 Things for STRO Stock Investors...
Sutro Biopharma Inc. (NASDAQ: STRO) made a huge gain to close out the week after the firm provided an update from its ongoing dose-escalation in its ovarian cancer trial.
SOUTH SAN FRANCISCO, Calif., Dec. 3, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicatio...
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicati...
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicati...
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development, and manufacturing company, today announced that C...
SOUTH SAN FRANCISCO, Calif., Nov. 5, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicatio...
Week 39 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
SOUTH SAN FRANCISCO, Calif., Sept. 9, 2020 /PRNewswire/ -- Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 2, 2020 /PRNewswire/ -- Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2020 /PRNewswire/ -- Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 /PRNewswire/ -- Sutro Biopharma, Inc.
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -1.69% and 7.66%, respectively, for the quarter ended June 2020.
Sutro Biopharma, Inc. (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Sutro Biopharma (NASDAQ: STRO) shares are trading lower on Thursday after Wells Fargo initiated coverage on the stock with an Overweight rating and an $18 price target.
SOUTH SAN FRANCISCO, Calif., June 22, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicati...
SOUTH SAN FRANCISCO, Calif., June 9, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicatio...
These four cancer therapeutics stocks are poised to experience long-term growth. An investment in any of these today could bring huge rewards.
SAN FRANCISCO, May 21, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise p...
SOUTH SAN FRANCISCO, Calif., May 21, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicatio...
SOUTH SAN FRANCISCO, Calif., May 14, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its ...
Sutro Biopharma: Revenue-Generating Platform Positioned For Growth
As of late, it has definitely been a great time to be an investor Sutro Biopharma
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 16.88% and 21.22%, respectively, for the quarter ended December 2019.
Sutro Biopharma's Platform Technology Makes It A Promising Oncology Pick For 2020
About STRO
Sutro Biopharma operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and... [Read more...]
| Industry Biotechnology | IPO Date Sep 27, 2018 |
| CEO William Newell | Employees 182 |
| Stock Exchange NASDAQ | Ticker Symbol STRO |
Financial Performance
In 2019, STRO's revenue was $42.74 million, an increase of 11.24% compared to the previous year's $38.42 million. Losses were -$55.74 million, 57.8% more than in 2018.
Analyst Forecasts
According to 8 analysts, the average rating for STRO stock is "Strong Buy." The 12-month stock price forecast is 28.57, which is an increase of 7.24% from the latest price.